...
首页> 外文期刊>Journal of Medicinal Chemistry >Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones
【24h】

Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones

机译:结合有苯基恶唑烷酮的HIV-1蛋白酶抑制剂的基于结构的设计,合成和构效关系研究

获取原文
获取原文并翻译 | 示例

摘要

A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar antiviral potency against patient-derived viruses from HIV-1 clades A, B, and C, and most retained potency against drug-resistant viruses. Further optimization of these compounds using structure-based design may lead to the development of novel protease inhibitors with improved activity against drug-resistant strains of HIV-1.
机译:设计并合成了一系列具有羟乙胺核心和不同苯基恶唑烷酮P2配体的新型HIV-1蛋白酶抑制剂。 P2和P2'部分的苯基取代变化显着影响抑制剂的结合亲和力和抗病毒效力。通常,在P2具有2-和4-取代的苯基恶唑烷酮的化合物表现出比3-取代的类似物更低的结合亲和力。配体-酶复合物的晶体结构分析显示,蛋白酶S2结合口袋中2和3取代的P2部分具有不同的结合模式,这可能解释了它们的不同结合亲和力。具有3个取代的P2部分的几种化合物对来自HIV-1进化枝A,B和C的患者衍生病毒表现出皮摩尔结合亲和力和低纳摩尔抗病毒效力,并且对耐药性病毒的保留力最大。使用基于结构的设计对这些化合物进行进一步优化可能会导致开发出具有针对HIV-1耐药株的改良活性的新型蛋白酶抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号